The automated facility was previously owned by AstraZeneca and is well designed for high-volume commercial production, AGC noted. It contains two 20,000-liter stainless steel mammalian cell bioreactors with room for four additional bioreactors and has more than twenty acres for future expansion.

Image courtesy of AGC Biologics.

AGC plants to run full-scale operations at the new facility by April 2021. It will help the company advance a higher ratio of late-phase and commercial products and support a wider range of commercial demand, the company noted.

In addition, AGC will complete facility expansion projects in Seattle, Denmark, and Japan this year and in early 2021.

AGC to manufacture Takara Bio's COVID-19 vaccine
In the fight against COVID-19, AGC Biologics, a contract development and manufacturing organization, is partnering with Takara Bio to manufacture plasmid...

AGC Biologics, Faron to manufacture cancer immunotherapy
Contract development and manufacturing organization AGC Biologics has formed a cancer immunotherapy partnership with Faron Pharmaceuticals.

AGC Biologics, AdaptVac partner on COVID-19 vaccine
AGC Biologics, a contract development and manufacturing organization, and AdaptVac have teamed up to develop a COVID-19 vaccine.